ArticleBMC cancer2025
Integrative analysis identifies radiotherapy resistance-associated CAF subtypes shaping the tumor immune landscape in breast cancer.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Emerging Approaches in Breast Cancer: From Molecular Mechanisms to Diagnosis and Therapeutic Strategies.Oncology research · 2026Review
- Fibroblasts as a ruler of the immune microenvironment: measurement and modulation in tissue homeostasis and disease.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundCancer-associated fibroblasts (CAFs) play a critical role in the tumor microenvironment (TME) of breast cancer (BC), influencing immune evasion and treatment resistance. This study aims to explore the heterogeneity of CAFs and their impact on prognosis and radiotherapy resistance.
methodsSingle-cell RNA sequencing was used to analyze CAF subsets in BC. Three major CAF subpopulations were identified, including inflammatory CAFs (iCAFs) and matrix-modulating CAFs (mmCAFs), which were enriched in Scissor⁺ cells associated with prognosis. A CAF-derived gene signature was constructed to stratify BC patients into transcriptome clusters with varying TME compositions. Survival analysis and multivariate regression were employed to assess the prognostic value of the gene signature and predict radiotherapy resistance. Validation was conducted using METABRIC and GEO cohorts.
resultsThe iCAF and mmCAF subsets exhibited high stemness potential and facilitated immune rejection through interactions with epithelial and immune cells. The CAF gene signature identified high-risk clusters with increased stromal infiltration, suppressed CD8⁺ T-cell responses, and activation of immune-suppressive pathways, including VEGF. These high-risk clusters were significantly associated with radiotherapy resistance. A five-gene CAF risk model was developed, which robustly predicted radiotherapy resistance and poor prognosis in multiple cohorts. Validation confirmed the expression of risk genes, such as ENO1, which correlates with poor survival, TP53 mutation, and resistance to radiotherapy.
conclusionsCAFs play a pivotal role in TME remodeling, immune evasion, and treatment resistance in BC. The CAF-derived gene signature offers a clinically applicable tool for risk stratification, predicting prognosis and radiotherapy resistance. Targeting CAFs may provide new therapeutic opportunities for improving breast cancer treatment outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.